Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

NCT05399654 is registered in ClinicalTrials.gov with Tallac Therapeutics as lead sponsor.

NCT NCT05399654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05399654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Lead sponsor
Tallac Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 28, 2022
Completion date
May 19, 2026
Enrollment
72 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors